好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Clinical Characteristics of Fast and Slow Progressors of Infarct Growth in Anterior Circulation Large Vessel Occlusion Stroke
Cerebrovascular Disease and Interventional Neurology
S20 - Cerebrovascular Disease: Large Vessel Occlusions and Thrombectomy (5:18 PM-5:30 PM)
010

To determine clinical variables associated with fast or slow progressors of early infarct growth in anterior circulation large vessel occlusion (ACLVO) stroke.

 
Fast and slow progressors are phenotypes of ischemic tolerance to ACLVO stroke that are observed in practice but remain poorly understood.  

Single-center retrospective study of patients with intracranial ICA or MCA occlusion, with or without tandem cervical ICA occlusion, who underwent baseline CT perfusion or MRI within 24 hours of stroke onset.  Fast progressors (ischemic core > 70 ml, < 6 hours of stroke onset) and slow progressors (ischemic core ≤ 30 ml, > 6 to 24 hours of stroke onset) were identified.   Demographics, co-morbidities, admission NIHSS and ACLVO subtypes were tested in univariate and multivariate analysis for association with fast or slow progressor phenotype.

185 patients were included with mean age 71 ± 15 and NIHSS 17 ± 7; 60% were female.  Patients had occlusion of the MCA in 72% or the intracranial ICA in 28% of cases, of which 20% had tandem cervical ICA occlusion. In the early epoch, there were no significant differences in age, sex, NIHSS, co-morbidities or ACLVO subtype between fast progressors (n=19) versus controls (n=56).  In the delayed epoch, mean NIHSS was 14 ± 6 in slow progressors (n=61) versus 19 ± 7 in controls (n=49).  Slow progressors had MCA occlusion in 80% versus 63% (p < 0.05) and tandem occlusion in 10% versus 35% of controls (p < 0.01).  Multivariate regression showed that age (OR 1.04, 95% CI  1.01-1.07) and NIHSS (OR 0.87, 95% CI 0.81-0.93) but not ACLVO subtype were independently associated with slow progressor status. 

Slow progressors had greater frequency of MCA occlusion and absence of tandem ICA occlusion relative to non-slow progressors.  However, only age and NIHSS were independently associated with slow infarct progression in late presenting patients.
Authors/Disclosures
Marcelo Rocha, MD, PhD (UPMC)
PRESENTER
The institution of Dr. Rocha has received research support from NIH.
Shashvat Desai, MD (University of Pittsburgh Medical Center) Dr. Desai has nothing to disclose.
Ashutosh P. Jadhav, MD, FAAN (Barrow Neurological Institute) Dr. Jadhav has nothing to disclose.
Tudor G. Jovin, MD (Cooper University Healthcare) Dr. Jovin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerenovus. Dr. Jovin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Contego Medical. Dr. Jovin has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Several law firms. Dr. Jovin has stock in Corindus. Dr. Jovin has stock in Methinks. Dr. Jovin has stock in Viz.ai. Dr. Jovin has stock in Route92. Dr. Jovin has stock in FreeOx Biotech. Dr. Jovin has stock in Galaxy. Dr. Jovin has stock in Kandu. The institution of Dr. Jovin has received research support from Stryker. The institution of Dr. Jovin has received research support from Medtronic.